Combination formulation of two antiviral compounds
Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
1. A pharmaceutical composition comprising:
a) a solid dispersion comprising Compound I dispersed within a polymer matrix comprising copovidone, Compound I having the formula:
wherein Compound I is substantially amorphous; and
b) about 25% w/w of substantially crystalline sofosbuvir having the formula:
2. The pharmaceutical composition of claim 1 , wherein the weight ratio of Compound I to copovidone in the solid dispersion is from about 5:1 to about 1:5.
3. The pharmaceutical composition of claim 2 , wherein the weight ratio of Compound I to copovidone in the solid dispersion is from about 2:1 to about 1:2.
4. The pharmaceutical composition of claim 3 , wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1.
5. The pharmaceutical composition of claim 1 , comprising from about 1% to about 20% w/w of the solid dispersion.
6. The pharmaceutical composition of claim 1 , wherein the crystalline sofosbuvir has XRPD 2θ-reflections at about:
(1) 7.5, 9.6, and 18.3 °2θ±0.2;
(2) 5.0, 7.3, and 18.1 °2θ±0.2;
(3) 6.9, 24.7, and 25.1 °2θ±0.2;
(4) 19.7, 20.6, and 24.6 °2θ±0.2;
(5) 5.0, 6.8, and 24.9 °2θ±0.2;
(6) 5.2, 6.6, and 19.1 °2θ±0.2; or
(7) 6.1, 20.1, and 20.8 °2θ±0.2.
7. The pharmaceutical composition of claim 1 , wherein the crystalline sofosbuvir has XRPD 2θ-reflections at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3 °2θ±0.2.
8. The pharmaceutical composition of claim 1 , wherein the crystalline sofosbuvir has XRPD 2θ-reflections at about: 6.1 and 12.7°2θ±0.2.
9. The pharmaceutical composition of claim 1 , further comprising a diluent, a disintegrant, a lubricant, or any combination thereof.
10. The pharmaceutical composition of claim 9 , wherein the diluent is selected from the group consisting of dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, lactose, lactose monohydrate, mannitol, microcrystalline cellulose, starch, tribasic calcium phosphate, and combinations thereof.
11. The pharmaceutical composition of claim 10 , wherein the diluent is microcrystalline cellulose and is present in an amount of about 15% w/w.
12. The pharmaceutical composition of claim 9 , wherein the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, microcrystalline cellulose, modified corn starch, povidone, pregelatinized starch, sodium starch glycolate, and combinations thereof.
13. The pharmaceutical composition of claim 12 , wherein the disintegrant is croscarmellose sodium and is present in an amount of about 5% w/w.
14. The pharmaceutical composition of claim 9 , wherein the lubricant is selected from the group consisting of calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, and combinations thereof.
15. The pharmaceutical composition of claim 14 , wherein the lubricant is magnesium stearate and is present in an amount of about 1.5% w/w.
16. The pharmaceutical composition of claim 1 , further comprising
c) about 5% to about 35% w/w microcrystalline cellulose,
d) about 1% to about 10% w/w croscarmellose sodium, and
e) about 0.1% to about 3% w/w magnesium stearate.
17. The pharmaceutical composition of claim 5 , further comprising
c) about 15% w/w microcrystalline cellulose,
d) about 1% to about 10% w/w croscarmellose sodium, and
e) about 0.1% to about 3% w/w magnesium stearate.
18. The pharmaceutical composition of claim 1 , wherein the composition is formulated for immediate release.
19. A pharmaceutical dosage form comprising the pharmaceutical composition of claim 1 , comprising from about 5 mg to about 100 mg of Compound I.
20. The pharmaceutical dosage form of claim 19 , comprising from about 5 mg to about 50 mg of Compound I.
21. The pharmaceutical dosage form of claim 19 , comprising about 50 mg of Compound I.
22. The pharmaceutical dosage form of claim 19 , comprising from about 100 mg to about 700 mg of sofosbuvir.
23. The pharmaceutical dosage form of claim 19 , comprising about 150 mg of sofosbuvir.
24. The pharmaceutical dosage form of claim 19 , comprising about 200 mg of sofosbuvir.
25. A tablet comprising the pharmaceutical dosage form of claim 19 .
26. A method of treating hepatitis C in a human patient in need thereof comprising administering to the patient the pharmaceutical composition of claim 1 .
27. The method of claim 26 , wherein the pharmaceutical composition is administered for about 12 weeks or less.
28. The method of claim 26 , wherein a sustained virologic response is achieved by about 12 weeks.
29. The method of claim 26 , wherein a sustained virologic response is achieved by about 6 months.
30. The method of claim 26 , further comprising administering an additional therapeutic agent.
31. The method of claim 26 , wherein the pharmaceutical composition is administrable without regard to fed state.
32. The pharmaceutical composition of claim 1 , wherein the solid dispersion is a spray dried solid dispersion.
33. The pharmaceutical composition of claim 1 , wherein the substantially amorphous Compound I is greater than 99% amorphous.
34. The pharmaceutical composition of claim 1 , wherein the substantially crystalline sofosbuvir is greater than 99% crystalline.